Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

No BS RX vs QuickMD

By GLP-1 ScorecardUpdated

No BS RXFactor scores not reassessed.
Site position #23

Higher score

QuickMDFactor scores not reassessed.
Site position #248

Lower score

Score comparison

No BS RX has the higher recorded score — 82.8/100 to 64.9/100.

No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.

Before you choose

QuickMD does not publish a semaglutide price, so its QuickMD review sets out what it does disclose, while the No BS RX review explains the conditions attached to No BS RX's figure. The semaglutide cost page compares published rates across the field. Ask QuickMD for a written total before treating either one as the cheaper choice.

If neither one fits, No BS RX vs Recovery Delivered and NuDay Rx vs QuickMD compare each of them with another graded program, and the list of alternatives to No BS RX ranks the programs closest to No BS RX on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the Belle Health review covers one graded close to these two, at 73.8/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueNo BS RX +47
92
45
Dose & formulationNo BS RX +14
90
76
Clinical oversightQuickMD +14
72
86
Labs & monitoringNo BS RX +16
68
52
FulfillmentNo BS RX +23
94
71
Contract termsNo BS RX +13
74
61
No BS RX · top barQuickMD · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricNo BS RXQuickMD
WeighScore82.8/10064.9/100
GradeB−C
Site position#23#248
Semaglutide$149/mo advertised for standard compounded injection; low-dose priced separatelyMedication priced separately by pharmacy
Tirzepatide$225/mo advertised for standard compounded injection; low-dose priced separatelyMedication priced separately by pharmacy
CoverageConfirm program availability for your stateConfirm weight-loss visits in your state
Brand-name accessYesYes
Oral / sublingualYesYes
No BS RX

Site position #23 · B−

Factor scores not reassessed.

Strengths

  • Displays monthly and prepaid amounts by program
  • Advertises consultation, medication, shipping and messaging in the compounded plans
  • Lists branded Ozempic and Zepbound separately

What to consider

  • The $115 headline applies to low-dose programs
  • Plans renew automatically at the then-current rate
  • Cancellation generally stops future billing without refunding the current period
QuickMD

Site position #248 · C

Factor scores not reassessed.

Strengths

  • Publishes a standalone visit price
  • No membership advertised for weight-loss visits
  • Clinician can send an appropriate prescription to a local pharmacy

What to consider

  • Pharmacy charge depends on the prescription and coverage
  • Completed visits are nonrefundable even without a prescription
  • Missed or late-canceled visits incur a $35 deduction from visit credit

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard